Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Investor's Business Daily on MSN9d
Why Moderna Stock Has Surged 15% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
On today's call are Stéphane Bancel, Chief Executive Officer; Jamey Mock, Chief Financial Officer; and Stephen Hoge, President. Before we begin, please note that this conference call will include ...
President Stephen Hoge noted progress in pivotal studies for respiratory and non-respiratory vaccines. He shared updates on approvals filed for next-gen COVID, RSV, and flu-COVID combination ...
CompanyOverview\|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.
Stephen Hoge, President: Regarding Norovirus, GBS occurs in the background population, and we paused activities to prioritize patient safety. The FDA placed us on hold while reviewing our ...
“The virus is changing its stripes, and we will change to make sure we can beat the virus where it’s going,” Stephen Hoge, the president of Moderna, tells The Washington Post. A study from Moderna ...
Stephen Hoge, President: Regarding Norovirus, GBS occurs in the background population, and we paused activities to prioritize patient safety. The FDA placed us on hold while reviewing our documents, ...
On today's call are Stéphane Bancel, Chief Executive Officer; Jamey Mock, Chief Financial Officer; and Stephen Hoge, President. Before we begin, please note that this conference call will include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback